International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2019
- PMID: 40513636
- DOI: 10.1016/j.fertnstert.2025.06.003
International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology, 2019
Abstract
Objective: To report the utilization, effectiveness, and safety of assisted reproductive technologies (ARTs) in 2019.
Design: A retrospective, cross-sectional survey derived from cycle and pregnancy outcome data submitted by national and regional registries.
Subjects: Patients undergoing ART procedures.
Intervention: Assisted reproductive technology.
Main outcome measures: Outcomes on country, regional, and global levels.
Results: There were 3,544,683 cycles with 783,073 infants born reported. There were an estimated ≥3,855,694 cycles with >865,914 infants in reporting countries including nonreporting clinics. The reported number of cycles and infants increased by approximately 8% from 2018. Autologous frozen-thawed transfers accounted for 61.8% of all autologous transfers without preimplantation genetic testing (PGT), up from 14.8% in 2015. Among all reporting countries, the percentage of freeze-all cycles was 38.4% in 2019, up from 24.6% in 2015. There were 233,833 initiated PGT cycles reported from 44 countries, representing 6.6% of reported cycles vs. 2.6% in 2015. The delivery rate for autologous oocytes was 22.9% per aspiration, with a cumulative delivery rate of 38.6% per aspiration (excluding PGT). Per transfer, the delivery rates were 31.3% for autologous fresh transfers, 31.9% for autologous frozen transfers, 48.7% for transfers using PGT, and 34.6% for transfers after oocyte donation (combined fresh and frozen transfers).In fresh autologous cycles (excluding PGT), the mean number of transferred embryos was 1.51, the proportion of single embryo transfers was 55.6%, and the multiple delivery rate was 17.7%. In autologous frozen-thawed cycles (excluding PGT), the mean number of transferred embryos was 1.26, the proportion of single embryo transfers was 74.1%, and the multiple delivery rate was 13.0%. With oocyte donation (combined fresh and frozen transfers), the multiple delivery rate was 10.8%. The multiple delivery rate for cycles using PGT was 4.2%.
Conclusion: The International Committee for Monitoring Assisted Reproductive Technologies report is the most comprehensive summary of global ART utilization, effectiveness, and safety currently available. The report documents an increase in reported cycles and infants born from previous years, growing utilization of embryo cryopreservation and single embryo transfers, increasing numbers of PGT cycles, and a reduction in multiple deliveries. It also provides a benchmark for the impact of the coronavirus disease 2019 pandemic in 2020.
Keywords: Assisted reproductive technology; infertility; multiple deliveries; registry; single embryo transfer.
Copyright © 2025 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests S.D. reports consulting fees paid from Science for Africa Foundation to institution for participation in a research protocol development group, unrestricted grant paid from Ferring to institution in support of the African Registry and Network of Assisted Reproductive Technology, honorarium for presentation at educational symposia 2024, support for conference attendance as invited speaker (travel/accommodation), support to attend the Science and Technology Advisory Group, Human Reproduction Program World Health Organization, unpaid service as an ICMART Board member, Director of the African Registry and Network of Assisted Reproductive Technology and Observer, and Board of the African Federation of Fertility Societies, outside the submitted work. G.M.C. is the Director of the National Perinatal Epidemiology and Statistics Unit of the University of New South Wales, Sydney, which receives funding from the International Committee for Monitoring Assisted Reproductive Technologies (ICMART), to produce statistical tables for the ICMART World Report series. S.C.J. reports travel fee for lectures supported by Ferring, travel support from the Japan Society for Reproductive Medicine for attending meetings, and service on the advisory board of Ferring, outside the submitted work. V.L.B. provides an unpaid service as regional representative for ICMART and for past service for the Executive Council of the Society for Assisted Technology, received payment to institution from the National Institutes of Health and the Howard and Georgeanna Jones Foundation for research, and is a consultant for Ferring and IBSA; outside the submitted work. M.B. reports service on Board of Director, Patient Oriented Strategies Encompassing Individualised Oocyte Number (POSEIDON) Group; outside the submitted work. J.d.M. is Chair of Societe de Medecine de la Reproduction, France, unpaid, outside the submitted work. E.E. is Chairman For Board of Trustees, Egyptian Foundation of Reproductive Medicine and Embryology (EFRE), outside the submitted work. B.F. has nothing to disclose. O.I. has received honorarium for lectures from Ferring and Organon, outside the submitted work. M.S.K. reports travel support from Ferring, IBSA, and Merck and participates in European IVF Monitoring Consortium–European Society of Human Reproduction and Embryology, German IVF Registry, and ICMART, outside the submitted work. F.Z.-H. reports travel expenses and honorarium for a scientific lecture at a Ferring Pharma–sponsored international congress, Director, responsible for the Latin American Registry of Assisted Reproductive Technology, Chair Committee of Ethics and Public Policies, and Chilean Society of Obstetrics and Gynecology, Vice Chair ICMART, outside the submitted work. G.D.A. reports honoraria from Organon; travel support from the European Society of Human Reproduction and Embryology; Chair, ICMART, unpaid; President, World Endometriosis Research Foundation, unpaid; ICMART Liaison Observer, Board of the International Federation of Fertility Societies, unpaid; Member, Global Health Committee, American Society for Reproductive Medicine, unpaid; and Founder and Chief Executive Officer of Advanced Reproductive Care, Inc. (d/b/a ARC Fertility), outside the submitted work.
LinkOut - more resources
Full Text Sources
